Highest-materiality recent filing
Immix Biopharma terminates Richard Graydon; management sees no material impact
Richard Graydon terminated effective July 17, 2026, for reasons unrelated to his company activities.
Immix Biopharma shareholders elect directors and ratify Crowe LLP as auditor at 2026 annual meeting
All nine director nominees (including Ilya Rachman, Gabriel Morris, Jason Hsu) elected with over 35M votes each; broker non-votes ~6.4M.
Immix Biopharma prices $150M public offering of 16.8M shares at $8.94
Gross proceeds $150M; net proceeds ~$140.65M after discounts and expenses.
Immix Biopharma reports 95% CR rate in NEXICART-2; all MRD-negative patients convert to CR
All four MRD-negative relapsed/refractory AL Amyloidosis patients from ASH 2025 have converted to complete response (CR).
Immix Biopharma completes NEXICART-2 enrollment; topline results Q3 2026
Enrollment complete for 40-patient BLA-enabling Phase 2 trial NEXICART-2 (NCT06097832) in relapsed/refractory AL Amyloidosis.
Immix Biopharma ups ATM offering to $100M from $50M
Increased max aggregate offering price under ATM agreement from $50M to $100M.
Immix Biopharma reports 75% CR rate in Phase 2 NXC-201 for AL amyloidosis, BLA plan 2026
NXC-201 achieved 75% complete response (15/20) by independent review committee in relapsed/refractory AL amyloidosis.
Immix Biopharma raises ~$93.7M net via 19.1M share and warrant offering at $5.10
19,117,646 shares at $5.10/share and 490,196 pre-funded warrants at $5.09/warrant in underwritten offering.
Immix Biopharma files updated auditor consents for S-3 registration
Filed updated consents from former auditor KMJ Corbin and current auditor Crowe LLP, dated Nov 26, 2025.
Immix Biopharma raises $9.1M in PIPE; Nancy Chang appointed to board
Sold 3,831,216 shares at $2.37/share and warrants for 2,873,417 shares at $2.00/share.
Immix Biopharma stockholders elect 8 directors and ratify Crowe LLP as 2025 auditor
All 8 director nominees elected with 'for' votes ranging from 13.4M to 14.6M; broker non-votes 5.5M across all director proposals.
Immix Biopharma enters ATM equity offering with Citizens JMP Securities
Agreement allows at-the-market sales of common stock; 3% commission to Agent.
Immix Biopharma subsidiary Nexcella awarded $8M CIRM grant for NXC-201 AL Amyloidosis trial
$8 million CLIN2 grant from California Institute for Regenerative Medicine to support NXC-201 CAR-T therapy for relapsed/refractory AL Amyloidosis.
Immix Biopharma replaces auditor KMJ Corbin with Crowe LLP after KMJ partners join Crowe
Effective July 17, 2024, Immix dismissed KMJ Corbin & Company LLP and appointed Crowe LLP as its independent registered public accounting firm.
Immix Biopharma shareholders approve 3M-share increase and evergreen provision in equity plan
Shareholders approved increasing omnibus equity plan shares by 3,000,000 to 4,934,561 total.
Immix Biopharma completes short-form merger of majority-owned subsidiary Nexcella
On May 20, 2024, Immix merged its >95%-owned subsidiary Nexcella into itself; Nexcella ceased to exist.
Immix Biopharma prices $15M public offering of 5.5M shares at $2.71/share
Offering of 5,535,055 shares at $2.71 per share; gross proceeds ~$15M before expenses.
Immix Biopharma suspends at-the-market equity offering under Sales Agreement with ThinkEquity
Suspended prospectus supplement dated July 14, 2023; no sales of common stock until new filing.
Immix Biopharma raises $10M via private placement; appoints new director
Gross proceeds of ~$10M from sale of 3.24M shares at $1.94/share and 1.91M pre-funded warrants at $1.9399.
Immix Biopharma enters ATM equity offering agreement with ThinkEquity LLC
ATM Sales Agreement with ThinkEquity LLC allows at-the-market sales of common stock, subject to $75M public float limitation.
Immix Biopharma shareholders elect 7 directors, ratify auditor, approve equity plan
All seven director nominees elected: Rachman, Morris, Hsu, Marquet, Adams, Ng, Buchan.
Immix Biopharma enters ATM facility to sell up to $5M in common stock
ATM Sales Agreement with ThinkEquity LLC for up to $5,000,000 of common stock.
Immix Biopharma amends 8-K to clarify no deposits at Silvergate or Silicon Valley Bank
Filing corrects original 8-K's item number from 1.01 to 7.01 for Regulation FD disclosure.
Immix Biopharma confirms no deposits at Silvergate or Silicon Valley Bank
Neither Immix Biopharma nor its subsidiaries hold cash deposits or securities at Silvergate Bank or Silicon Valley Bank.
Immix Biopharma subsidiary Nexcella raises ~$650k in private placement at $6.49/share
Nexcella entered share purchase agreements with accredited investors for 100,152 shares at $6.49/share.
Immix Biopharma to use Nexcella slide presentation in investor meetings; no specifics given
Slide presentation of wholly-owned subsidiary Nexcella to be used in third-party meetings.
Immix Biopharma in-licenses NXC-201 CAR-T with 71% complete response in multiple myeloma
In-licensed exclusive worldwide rights (ex-Israel/Middle East) to NXC-201 (BCMA-targeted CAR-T) from Hadasit and BIRAD.
Immix Biopharma stockholders elect seven directors, ratify auditor at annual meeting
All seven director nominees elected: Ilya Rachman, Gabriel Morris, Jason Hsu, Magda Marquet, Helen C. Adams, Carey Ng, Jane Buchan.
100% of patients completed planned treatment cycles with IMX-110 without drug-related interruptions in ongoing Phase 1b/2a trial.
Immix Biopharma reports IMX-110 50% response rate in STS mouse study, beating standard of care
IMX-110 as monotherapy achieved 50% response rate in first-line-therapy-resistant STS mouse study, vs 0% for doxorubicin.
Immix Biopharma gets FDA Rare Pediatric Disease designation for IMX-110 in rhabdomyosarcoma
FDA granted Rare Pediatric Disease designation for IMX-110 to treat rhabdomyosarcoma, a life-threatening pediatric cancer.
Immix Biopharma closes IPO of 4.2M shares at $5.00/share for $21M gross proceeds
IPO closed Dec 20, 2021; shares began trading on Nasdaq Dec 16 under IMMX.
Effective August 22, 2023 and in connection with the closing of the Private Placement, the Board of Directors (the “Board”) of the Company appointed Yekaterina Chudnovsky as a member of the Board
Max materiality 0.85 · Median 0.50 · Most common event other_material